Articles tagged with In Vitro Assays
AcCELLerate has partnered with ATCC to provide customized Master, Working, and assay-ready instaCELL banks for research clients. Researchers will gain access to high-quality, authenticated cell lines with increased assay reproducibility.
A new human lung alveolus chip model enables investigation of viral replication, inflammatory responses, and genetic off-target effects of a novel pan-influenza CRISPR therapy. The study achieved significant reductions in virus load and host inflammatory response after a single administration.
Researchers developed patient-specific Cancer Chips to model esophageal tumor microenvironments, enabling accurate prediction of chemotherapy responses. The approach can rapidly stratify patients into responders and non-responders, paving the way for personalized medicine.
Researchers developed a new system, MEMPHIS, that models mRNA vaccine responses in a dish, providing insight into vaccine activity in vulnerable populations. The study found muted innate immune responses in people over age 60, indicating an impaired ability to support Th1 immunity.
Researchers develop physiologically relevant model to investigate breast cancer bone metastasis, holding promise for predicting risk and developing new treatments.
Researchers developed a compact 'gene scissor' tool, TnpB, which shows a 4.4-fold increase in efficiency of modifying DNA, making it more effective as a gene editing tool. The tool can be used to treat patients with familial hypercholesterolemia, reducing cholesterol levels by nearly 80%.
A high-throughput analysis of 26 medically important snakes in sub-Saharan Africa reveals the benefits of an integrated approach to understanding their venom composition and function. The study provides a solid foundation for further research on snake biology and antivenom development.
A new serological test, PepSeq, allows scientists to quickly test antibody binding against hundreds of thousands of protein targets, helping prepare for and respond to pandemics. The technology identifies specific antibodies that provide protection against infection, holding promise for developing effective vaccines and treatments.
An international research team developed an animal-free testing battery to detect developmental neurotoxicity, using human cells instead of animals. The results show that the testing battery is technically feasible and already has a measurement sensitivity comparable to animal experiments.
A recent study published in Applied In Vitro Toxicology found that tobacco-free nicotine pouches exhibit reduced levels of toxicants and biological activity compared to combustible cigarette smoke. The products, manufactured by Imperial Brands, showed substantially reduced genotoxicity and cytotoxicity in three toxicological assays.
A new study found that Omicron's immune-evading capabilities are significant, but some vaccinated and previously infected individuals have 'stronger' protection. However, the protection from Omicron may be compromised over time.
Researchers from FAU and MIT develop a microfluidic assay to study the mechanical performance of red blood cells under hypoxic conditions. The study reveals that cyclic hypoxia can lead to mechanical degradation of the red blood cell membrane, contributing to aging.
A new assay using HEPATOPAC model identifies drugs with high DILI risk, showing high sensitivity and specificity. BioIVT's advanced in vitro liver model provides a promising solution for preclinical DILI risk assessment.
New research by British American Tobacco indicates that modern oral nicotine products (MOPs) are less biologically active than traditional cigarettes and snus, with some products failing to elicit a biological response. The study suggests MOPs may be a reduced-risk option for users who switch completely from smoking.
Researchers found that PFASs, such as PFOS and PFNA, have high binding affinities to Baikal seal PPARα, suggesting a role in toxicity. In vitro and in silico approaches revealed interspecies differences in the binding of PFASs to PPARα.
The novel vaping product produced greatly reduced mutagenicity and cytotoxicity compared to cigarette smoke. Further studies are required to substantiate its potential as a reduced-risk product.
Researchers discovered a link between BSEP inhibition and FXR activation, explaining the weak concordance between BSEP inhibition potency and cholestatic DILI incidence. The C-DILI assay has been shown to have high in vitro-in vivo correlation among compounds known to have a risk of DILI.
Research highlights the effects of nanoparticles on platelet activation and plasmatic coagulation, a complex process essential for human life. Studies demonstrate that nanoparticles can alter hemostasis in various diseases, such as cancer and diabetes, emphasizing the need for thorough testing and regulation.
The symposium aims to improve science-informed hazard prediction and risk assessment for pesticides and other agrochemicals. New approaches, including high-throughput methods, are being developed to reduce the use of animal testing and increase transparency in risk assessments.
Bioengineering professor Dimitrios Morikis and research scientist Monte Radeke are searching for chemical compounds targeting the complement system to treat age-related macular degeneration. They will use computational screening, experimental testing, and human retinal cell-based models to identify potential treatments.
A recent study by researchers from Lawrence Berkeley National Laboratory found that thirdhand smoke causes significant genetic damage in human cells. Chronic exposure is worse than acute exposure, with higher concentrations of chemical compounds causing more DNA damage over time.